Abstract

To explore the effects of sertraline combined with repetitive transcranial magnetic stimulation on clinical efficacy, negative emotions and cognitive function in adolescent patients with depressive disorders and anxious features was the objective of this study. This study selected 119 adolescent individuals with depressive disorders and anxious features who were admitted to The First Affiliated Hospital of Air Force Military Medical University from April 2019 to April 2022 and followed up for 1 y. All the individuals were divided into control (n=55) and research groups (n=64). The control group received sertraline and a research group receiving sertraline with repetitive transcranial magnetic stimulation. The clinical efficacy, negative emotions, cognitive function, adverse event rate and recurrence rate were comparatively analyzed. Among them, negative emotions were mainly assessed by the Hamilton depression and anxiety scales scores. Similarly, cognitive function was evaluated by the Montreal cognitive assessment scale and Wisconsin card sorting test and adverse event rate was statistically analyzed by observing nausea, anorexia, dizziness and drowsiness. Compared with the control group, the total effective rate of the research group was significantly higher; scores of Hamilton depression and anxiety, number of wrong answers and persistent errors were significantly lower after treatment. Montreal cognitive assessment score, total number of replies, number of number of correct answers and number of number of classifications completed were significantly higher after treatment. No notable difference was identified between groups in the adverse event rate. However, the recurrence rate within 12 mo was lower in the research group. Sertraline combined with repetitive transcranial magnetic stimulation has a definite clinical effect on adolescent patients with depressive disorders and anxious features, which can significantly relieve anxiety and depression, and improve cognitive function while not increasing the risk of adverse drug events, with a lower 1 y recurrence risk.